Reply to “A comment on ‘Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was’”2025-09-180 PRE AI BB Rittenhouse *SSultan Othman Alolayan AAlissa R. Segal TTewodros Eguale DOI:10.1111/dom.70149OriginalOriginal request for helpShareSaveAbstract En